All posts by Daniel Bejan

  • PDX PHARMA WELCOMES A NEW SCIENTIST, DR. MOATAZ REDA

    8/13/2019

    PDX Pharma welcomes a new Scientist, Dr. Moataz Reda. Dr. Reda recently graduated from Oregon Health and Science University with a doctorate degree in biomedical engineering. His dissertation thesis was on the development of novel nanoparticle based PLK1, EGFR, and PD-L1 targeted therapies for lung cancer. He is our top recruit and we are excited […]

  • PDX PHARMA WELCOMES A NEW RESEARCH ASSISTANT, RUIJIE WANG

    8/13/2019

    PDX Pharma welcomes a new Research Assistant, Ruijie Wang. Rujie recently graduated from University of Minnesota-Twin Cities with Bachelor of Science degree in Chemistry and a Minor in Pharmacology (GPA 3.57). Her undergraduate research experience in Dr. Zhengqiang Wang’s group involved the design and synthesis of TDP2 inhibitors — innovative drugs for cancer treatment. She […]

  • PDX PHARMA WELCOMES A NEW RESEARCH ASSISTANT, MOLLY HERINCKX

    6/26/2019

    PDX Pharma welcomes a new Research Assistant, Molly Herinckx. Molly recently graduated from Oregon State University with an Honors Bachelor of Science degree in Molecular Biology and Biochemistry, and Minors in Chemistry and Spanish (GPA 3.97). Her Honors College thesis project focused on engineering mutant strains of Streptomyces fungicidicus to analyze the effect of […]

  • Mr. Bejan has been accepted into Oregon Health and Science University’s PhD program as an ARCS Scholar

    4/29/2019

    Daniel Bejan joined PDX Pharmaceuticals in 2017 as a research assistant and has recently been accepted into OHSU’s graduate Program in Molecular and Cellular Biosciences (PMCB). Along with his acceptance to PMCB, Daniel was selected as an OHSU ARCS (Achievement Rewards for College Scientists) Foundation Scholar . ARCS is national non-profit women’s organization whose goal […]

  • Dr. Ngamcherdtrakul presents at the 2nd Annual Formulation & Drug Delivery USA Congress.

    3/20/2019

    Dr. Worapol Ngamcherdtrakul, a principal scientist of PDX Pharmaceuticals, gave a talk entitled “Versatile Nanoparticles For Delivery Of siRNAs, Cancer Drugs, And Vaccine Agents: Systemic And Topical Applications” on March 18th, 2019 at the 2nd Annual Formulation & Drug Delivery USA Congress in San Diego, CA.
    -Our versatile mesoporous silica nanoparticle platform has been designed and […]

  • Data on Functionalized Mesoporous Silica for Removing Heavy Metals Accepted for Publication in Scientific Reports (IF = 4.122)

    1/29/2019

    Data on mesoporous silica modified with 1,2-hydroxypyridinone (1,2-HOPO) for capturing gadolinium based contrast agents in vitro and in a chronic kidney disease rodent model have been recently published in Scientific Reports. The work was done in collaboration between PDX Pharmaceuticals, the Biomedical Engineering Department of Oregon Health and Science University, and the Pacific Northwest National […]

  • PDX Pharma welcomes a new Research Assistant, Husam Zaidan

    11/26/2018

    PDX Pharma welcomes a new Research Assistant, Husam Zaidan. Husam recently graduated from University of Oregon with a Major in Biochemistry and a Minor in Biology. His Honors College thesis project focused on the antioxidative effects of organic polysulfide H2S donors. He is our top pick among 120 applicants. We are excited to add him […]

  • President presents at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) Symposium

    9/21/2018

    PDX Pharma’s President/CEO, Dr. Wassana Yantasee, gave a talk on the “Development of a New Oral Drug for Treating Chronic Mercury Exposure” on September 8th, at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) Symposium, in Vermont.
    Highlights from her talk include:
    -Mesoporous silica functionalized with a dense thiol monolayer rug (SH-SAMMS) is much more […]

  • President serves as chair for the 2018 Nanomedicine and Drug Delivery Symposium (NANODDS)

    9/21/2018

    PDX Pharma’s President/CEO, Dr. Wassana Yantasee, will serve as chair for session IV of the 2018 Nanomedicine and Drug Delivery Symposium, hosted in Portland, Oregon (September 21-23). PDX Pharmaceuticals, in collaboration with Oregon Health and Science University’s biomedical engineering department, will present two posters at the conference:
    Nanoparticle-mediated co-delivery of taxane and siRNA to mirror the first […]

  • PDX Pharma met phase I SBIR milestones and is approved for starting the phase II SBIR project by the National Cancer Institute on 06/01/2018

    5/25/2018

    PDX Pharma has met all the milestones of the phase I portion of our fast-track SBIR project “Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer” and has been approved for starting the phase II portion of the project by the NCI. The project period is from 06/01/2018 to 05/31/2020.

  • President serves as the guest editor for the Bioengineering’s special issue “Nanoparticles in Therapeutic Applications”

    5/22/2018

    PDX Pharma’s President/CEO, Dr. Wassana Yantasee, is currently serving as the guest editor in the special issue “Nanoparticles in Therapeutic Applications” for the MDPI  Bioengineering  journal. The special issue focuses on nanoparticle development and applications in broad ranges of diseases and delivery routes.
    More information can be found here.

  • President has served as a reviewer for the ZRG1 IMST-L (55) ‘Innovative Research in Cancer Nanotechnology’ (R01) Study Section for the NIH

    5/22/2018

    PDX Pharma’s President/CEO, Dr. Wassana Yantasee, has served as a reviewer for the ZRG1 IMST-L (55)  PAR-17-240 ‘Innovative Research in Cancer Nanotechnology (IRCN)’ (R01) Study Section for the National Institute of Health (NIH), held in Washington DC on March 29, 2018.

  • Data on PDX-001 Accepted for Publication in PLoS One (IF=2.806)

    5/22/2018

    PDX Pharmaceuticals, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, has developed PDX-001 as a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ breast cancer. The work has been funded by fast-track phase I/II SBIR awards from the NIH/NCI as well as angel funds (the Prospect Creek Foundation […]

  • Data on PDX-001’s Lyophilization and Stability Accepted for Publication in International Journal of Nanomedicine (IF=4.383)

    5/22/2018

    PDX-001 is a targeted nanoparticle for delivery of therapeutic siRNA for treating HER2+ and triple-negative breast cancer. The development is a collaborative work between PDX Pharma and the Biomedical Engineering Department of OHSU. The work has been funded by fast-track phase I/II SBIR awards from NIH/NCI, a phase I SBIR award from NIH/NCATS, and angel […]

RECENT PRESENTATIONS ON OUR TECHNOLOGY

Development of antioxidant nanoparticle platform for delivery of siRNA and chemodrugs, Department of Chemistry Seminar Series, Portland State University, May 18th, 2018

Development of a Targeted Therapeutic and Radiation Sensitizer for Lung Cancer, 63rd annual Radiation Research Society (RRS) meeting, Cancun, MX, October 15th, 2017

siRNA-nanoparticles for treating drug-resistant breast cancer, Gordon RNA Technology, Ventura, CA, Feb 1-6. 2015

New methodologies for cancer target identification, personalized medicine in cancer care, and novel therapies based on nanomedicine, BDMS Meeting, Bangkok, Thailand, December 26, 2014 (invited).

OHSU’s effort to understand complex biological systems of cancer leading to targeted therapy with siRNA-nanoparticles, Siriraj School of Medicine, Bangkok, Thailand, December 22, 2014 (invited).

Bioreducible-crosslinked polymer coated mesoporous silica nanoparticles for siRNA targeted delivery to HER2+ breast cancer, 4th International Conference on Nanotek & Expo, San Francisco, CA, December 12, 2014 (invited).

Antibody-conjugated Nanoparticle Platform for Targeted Delivery of SiRNA to HER2+ Breast Cancer, BMES Annual Meeting 2014, San Antonio, TX, October 24, 2014.

SiRNA-mediated Targeting of HER2 as a Viable Approach for Treating Trastuzumab Resistant Breast Cancer, WIN Symposium 2014, Paris, France, June 23, 2014.

Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers, AACR Annual meeting 2014, San Diego, CA, April 9, 2014.

Nanoparticle Platform for siRNA Delivery with ROS Scavenging Properties for Treating Fibrosis, Keystone Symposium, Fibrosis: From Bench to Bedside (C4), Keystone, CO, March 24, 2014.

Development of a Nanoparticle platform for the Targeted Delivery of siRNA to HER2-positive Breast Cancers, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ , March 25, 2014.

Novel Oral Detoxification of Mercury, Cadmium, and Lead with Thiol-Modified Mesoporous Silica, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ, March 27, 2014.

Potential Use of Mesoporous Silica Nanoparticle for siRNA Delivery Agent and ROS Scavenger in Fibrotic Diseases, IEEE-Nanomed 2013, Phuket, Thailand, November 11, 2013.

Development of Lanthanide-loaded Mesoporous Silica Nanoparticles for Multi-parametric Single Cell Analysis by Mass Cytometry, IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.

Nanoparticle platform for targeted delivery of siRNA and chemotherapies, (keynote presentation), IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.

Nanoparticle platform for therapeutic siRNA delivery to HER2 positive breast cancer,  TechConnect World 2012 – Nanotech, Santa Clara, CA, June, 2012.